DTX2 and cancer: Therefore, it is possible that in some contexts AHRR mechanisms may be predominant as opposed to PARP7-DTX2-mediated degradation of AHR, and this may at least in part explain why certain cancer cell lines are resistant to PARP7 inhibition (Gozgit et al, 2021).